Core Insights - KX-826 is emerging as a revolutionary solution for hair loss, developed by Kintor Pharmaceutical Limited, a company with over fifteen years of experience in dermatology [1][3] - The drug has shown excellent safety and efficacy in clinical trials for treating androgenetic alopecia in both men and women [3][5] Clinical Development - KX-826 has completed multiple clinical trials in China and the United States, demonstrating a strong safety profile and significant therapeutic effects [3][5] - In a recent phase II clinical study in China, KX-826 achieved its primary endpoint with a statistically significant increase of approximately 22 hairs/cm in target area non-vellus hair counts for both 0.5% and 1.0% BID groups [5] - The study also reported no drug-related sexual dysfunction adverse reactions, indicating a favorable safety profile [5] Product Differentiation - KX-826 is distinct from conventional treatments like minoxidil and finasteride, as it does not cause an oily residue or a shedding phase, and is suitable for both genders without causing sexual side effects [4][5] - The product leverages advanced research in scalp biology to strengthen hair from the roots [4] Brand Expansion - Kintor launched the KOSHINÉ brand in the second half of 2024, featuring high-end cosmetics aimed at making dermatological innovations accessible to consumers [7] - The KOSHINÉ Hair Care Line includes five anti-hair loss solutions, while the Skincare Line features products formulated with KX-826 and KT-939 [8] Consumer Reception - Early users of KOSHINÉ products report positive experiences, noting improvements in hair fullness and scalp condition without the typical side effects associated with hair loss treatments [10] - The brand has gained traction in the global market, utilizing online channels for consumer outreach [13] Purchase Channels - KOSHINÉ products are available through the Amazon USA Selected Store and the official KOSHINÉ Mall, providing easy access for consumers [15]